Torben Frøstrup Hansen

Medicin og biovidenskab

1. Colorectal Neoplasms 100%
2. Colonic Neoplasms 68%
3. MicroRNAs 63%
4. Circulating Tumor DNA 49%
5. Neoplasms 38%
6. Drug Therapy 33%
7. Rectal Neoplasms 31%
8. Oxaliplatin 31%
9. Biomarkers 29%
10. Bevacizumab 29%
11. Survival 23%
12. Capecitabine 21%
13. Natural Killer Cells 20%
14. Progression-Free Survival 20%
15. Therapeutics 19%
16. Single Nucleotide Polymorphism 18%
17. Lung Neoplasms 17%
18. Vascular Endothelial Growth Factor A 17%
19. Biliary Tract Neoplasms 15%
20. Prostatic Neoplasms 15%
21. Epidermal Growth Factor 14%
22. Circulating MicroRNA 13%
23. Microvessels 12%
24. Genes 12%
25. DNA 12%
26. Genome-Wide Association Study 11%
27. Panitumumab 11%
28. Recurrence 11%
29. Confidence Intervals 10%
30. Vascular Endothelial Growth Factor Receptor-2 9%
31. Adenocarcinoma 9%
32. Tumor-Infiltrating Lymphocytes 9%
33. Population 9%
34. Angiogenesis Inhibitors 9%
35. Microsatellite Instability 8%
36. XELOX 8%
37. Systematic Reviews 8%
38. Methylation 8%
39. Denmark 8%
40. Castration 8%
41. Immunotherapy 8%
42. Combination Drug Therapy 8%
43. Bronchoalveolar Lavage 8%
44. Mutation 8%
45. Chemoradiotherapy 7%
46. Polymerase Chain Reaction 7%
47. Non-Small Cell Lung Carcinoma 7%
48. Neuropeptide Y 7%
49. Homeobox Genes 7%
50. Disease-Free Survival 6%